SRTD Biotech raised EUR 31.5 million in an oversubscribed seed round led by Mérieux Equity Partners and co-led by NRW.BANK and Boehringer Ingelheim Venture Fund. Lilly Ventures, HTGF and Anobis Asset also participated. The Jülich company develops selectively expressed RNA therapies designed to activate therapeutic payloads inside targeted diseased cells while limiting activity in healthy tissue. The capital will fund preclinical development across oncology, autoimmune disease and fibrosis programmes towards regulatory applications. SRTD also appointed Matthias Alder as chief executive following the financing. The technology remains preclinical, and no approved treatment or completed human clinical result was announced.
SRTD Biotech raises EUR 31.5m for targeted RNA therapies
Mérieux leads with NRW.BANK and Boehringer’s venture fund as co-leads.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


